Pending final contract, healthcare and pharmaceutical companies GSK and Sanofi announced an agreement with the UK government to supply 60 million doses of the partnership's COVID-19 vaccine, currently under development.
In a news release today, the BNT162b1 COVID-19 vaccine under development by Pfizer and BioNTech displayed early positive results in producing neutralizing antibodies from the partnership's Phase I/II trial.
ZyCoV-D received permission from the Drug Controller General of India - CDSCO for Phase I/II clinical trials to take place in India with human subjects
The inactivated vaccine was granted permission by the Drug Controller General of India, and the Ministry of Health & Family Welfare to begin...
We spoke with Pfizer today and confirmed October remains feasible but is contingent on successful aquisition of an Emergency Use Declaration
Entos Pharmaceuticals (Entos), a healthcare biotechnology company developing nucleic acid medicines with its Fusogenix drug delivery platform, today announced the selection of two lead candidates for a pan-coronavirus Fusogenix DNA vaccine (Covigenix)
Sinovac, a Beijing-based company producing a vaccine for COVID-19 today announced their "CoronaVac" vaccine concluded preliminary Phase I/II trials showing "favorable immunogenicity and safety profiles."
For key manufacturers, numbers are beginning to reflect the potential financial impact of vaccine development. Hopeful investors have surged the price of Moderna, whose press releases are dominating the news on vaccine development in the US. Recently....